104 related articles for article (PubMed ID: 17125805)
1. Roscovitine differentially affects CaV2 and Kv channels by binding to the open state.
Buraei Z; Schofield G; Elmslie KS
Neuropharmacology; 2007 Mar; 52(3):883-94. PubMed ID: 17125805
[TBL] [Abstract][Full Text] [Related]
2. Slowed N-type calcium channel (CaV2.2) deactivation by the cyclin-dependent kinase inhibitor roscovitine.
Buraei Z; Anghelescu M; Elmslie KS
Biophys J; 2005 Sep; 89(3):1681-91. PubMed ID: 15951378
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine.
De Azevedo WF; Leclerc S; Meijer L; Havlicek L; Strnad M; Kim SH
Eur J Biochem; 1997 Jan; 243(1-2):518-26. PubMed ID: 9030780
[TBL] [Abstract][Full Text] [Related]
4. Roscovitine, a cyclin-dependent kinase inhibitor, affects several gating mechanisms to inhibit cardiac L-type (Ca(V)1.2) calcium channels.
Yarotskyy V; Elmslie KS
Br J Pharmacol; 2007 Oct; 152(3):386-95. PubMed ID: 17700718
[TBL] [Abstract][Full Text] [Related]
5. Domain III regulates N-type (CaV2.2) calcium channel closing kinetics.
Yarotskyy V; Gao G; Peterson BZ; Elmslie KS
J Neurophysiol; 2012 Apr; 107(7):1942-51. PubMed ID: 22205645
[TBL] [Abstract][Full Text] [Related]
6. Roscovitine inhibits CaV3.1 (T-type) channels by preferentially affecting closed-state inactivation.
Yarotskyy V; Elmslie KS
J Pharmacol Exp Ther; 2012 Feb; 340(2):463-72. PubMed ID: 22088954
[TBL] [Abstract][Full Text] [Related]
7. State-dependent block of HERG potassium channels by R-roscovitine: implications for cancer therapy.
Ganapathi SB; Kester M; Elmslie KS
Am J Physiol Cell Physiol; 2009 Apr; 296(4):C701-10. PubMed ID: 19244476
[TBL] [Abstract][Full Text] [Related]
8. Roscovitine: a novel regulator of P/Q-type calcium channels and transmitter release in central neurons.
Yan Z; Chi P; Bibb JA; Ryan TA; Greengard P
J Physiol; 2002 May; 540(Pt 3):761-70. PubMed ID: 11986366
[TBL] [Abstract][Full Text] [Related]
9. The separation of antagonist from agonist effects of trisubstituted purines on CaV2.2 (N-type) channels.
Buraei Z; Elmslie KS
J Neurochem; 2008 May; 105(4):1450-61. PubMed ID: 18221369
[TBL] [Abstract][Full Text] [Related]
10. (R)-roscovitine prolongs the mean open time of unitary N-type calcium channel currents.
DeStefino NR; Pilato AA; Dittrich M; Cherry SV; Cho S; Stiles JR; Meriney SD
Neuroscience; 2010 May; 167(3):838-49. PubMed ID: 20188151
[TBL] [Abstract][Full Text] [Related]
11. Open-state occupancy prevents gating charge relaxation of N-type (CaV2.2) calcium channels.
Yarotskyy V; Elmslie KS
Biophys J; 2009 Nov; 97(9):2446-55. PubMed ID: 19883587
[TBL] [Abstract][Full Text] [Related]
12. Temperature dependence of Cav1.4 calcium channel gating.
Peloquin JB; Doering CJ; Rehak R; McRory JE
Neuroscience; 2008 Feb; 151(4):1066-83. PubMed ID: 18206315
[TBL] [Abstract][Full Text] [Related]
13. The effects of presynaptic calcium channel modulation by roscovitine on transmitter release at the adult frog neuromuscular junction.
Cho S; Meriney SD
Eur J Neurosci; 2006 Jun; 23(12):3200-8. PubMed ID: 16820010
[TBL] [Abstract][Full Text] [Related]
14. A high-throughput assay for evaluating state dependence and subtype selectivity of Cav2 calcium channel inhibitors.
Dai G; Haedo RJ; Warren VA; Ratliff KS; Bugianesi RM; Rush A; Williams ME; Herrington J; Smith MM; McManus OB; Swensen AM
Assay Drug Dev Technol; 2008 Apr; 6(2):195-212. PubMed ID: 18471074
[TBL] [Abstract][Full Text] [Related]
15. The Timothy syndrome mutation of cardiac CaV1.2 (L-type) channels: multiple altered gating mechanisms and pharmacological restoration of inactivation.
Yarotskyy V; Gao G; Peterson BZ; Elmslie KS
J Physiol; 2009 Feb; 587(3):551-65. PubMed ID: 19074970
[TBL] [Abstract][Full Text] [Related]
16. HMJ-53A accelerates slow inactivation gating of voltage-gated K+ channels in mouse neuroblastoma N2A cells.
Chao CC; Shieh J; Kuo SC; Wu BT; Hour MJ; Leung YM
Neuropharmacology; 2008 Jun; 54(7):1128-35. PubMed ID: 18406431
[TBL] [Abstract][Full Text] [Related]
17. New Cav2 calcium channel gating modifiers with agonist activity and therapeutic potential to treat neuromuscular disease.
Wu M; White HV; Boehm BA; Meriney CJ; Kerrigan K; Frasso M; Liang M; Gotway EM; Wilcox MR; Johnson JW; Wipf P; Meriney SD
Neuropharmacology; 2018 Mar; 131():176-189. PubMed ID: 29246857
[TBL] [Abstract][Full Text] [Related]
18. Roscovitine binds to novel L-channel (CaV1.2) sites that separately affect activation and inactivation.
Yarotskyy V; Gao G; Du L; Ganapathi SB; Peterson BZ; Elmslie KS
J Biol Chem; 2010 Jan; 285(1):43-53. PubMed ID: 19887376
[TBL] [Abstract][Full Text] [Related]
19. Complex expression and localization of inactivating Kv channels in cultured hippocampal astrocytes.
Bekar LK; Loewen ME; Cao K; Sun X; Leis J; Wang R; Forsyth GW; Walz W
J Neurophysiol; 2005 Mar; 93(3):1699-709. PubMed ID: 15738276
[TBL] [Abstract][Full Text] [Related]
20. Cumulative activation of voltage-dependent KVS-1 potassium channels.
Rojas P; Garst-Orozco J; Baban B; de Santiago-Castillo JA; Covarrubias M; Salkoff L
J Neurosci; 2008 Jan; 28(3):757-65. PubMed ID: 18199775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
